文献速递消化内镜胰腺与胆道疾病消化道出血

肽优先止血策略用于ERCP乳头切开渗血:多中心非劣效RCT

A peptide-first hemostatic strategy for oozing-type postsphincterotomy bleeding during endoscopic retrograde cholangiopancreatography: a multicenter noninferiority randomized controlled trial (PROTECT-EST).
PubMed 文献 · Gastrointest Endosc · 2026-06-05

PROTECT-EST多中心非劣效RCT纳入130例EST后渗血≥180秒患者,比较自组装肽(SAP)与球囊压迫作为初始止血策略;SAP达到非劣效,预设探索性优效分析显示初始止血率更高、操作时间更短、补救器械使用更少,不良事件与迟发出血相似。

要点

  • SAP优先策略对EST后渗血止血非劣于球囊压迫。
  • 探索性分析显示SAP初始止血率92.3%高于球囊76.9%。
  • SAP组补救止血器械使用更少,操作时间更短。

核心结论

  • SAP优先策略对渗血型EST后即时出血的初始止血非劣于球囊压迫。
  • 预设探索性优效分析中SAP与更高的初始止血、更短操作时间和更少补救器械使用相关。
  • SAP可能成为实用的首选止血选择,但需外部验证。

研究设计与样本

  • 多中心、研究者发起的平行组随机对照非劣效试验,在日本三级转诊中心开展。
  • EST后渗血持续≥180秒且无自发性止血的成人按1:1随机分配至SAP涂抹或球囊压迫作为初始止血策略。
  • 共随机130例,SAP组65例,球囊组65例。
  • 主要终点为分配干预后≥3分钟无活动性渗血的初始止血成功;先检验非劣效,再作预设探索性优效分析。

主要发现

  • SAP达到预设非劣效标准。
  • 预设探索性优效分析中,SAP组初始止血成功60/65例(92.3%),球囊组50/65例(76.9%),风险差15.4个百分点(95%CI 3.1-27.7;P=.027)。
  • SAP组完成初始止血干预的平均时间更短。
  • SAP组补救止血器械使用更少(7.7% vs 23.1%;P=.033)。
  • 两组不良事件与迟发出血相似。

关键数值与推荐

  • 渗血型即时EST后出血定义:EST后渗血持续≥180秒且无自发性止血。
  • 初始止血成功定义:分配干预后≥3分钟无活动性渗血。
  • SAP组初始止血60/65例(92.3%),球囊组50/65例(76.9%),风险差15.4个百分点(95%CI 3.1-27.7;P=.027)。
  • 补救止血器械使用:SAP组7.7%,球囊组23.1%(P=.033)。

临床怎么用

  • 对EST后渗血持续≥180秒无自发性止血者,可考虑以SAP作为初始止血策略。
  • SAP优先策略可能提高初始止血成功率并减少补救器械使用。
  • 应用前需结合外部验证结果与本地可得性。

局限性

  • 优效性分析为预设探索性分析,需谨慎解读。
  • 研究在日本三级转诊中心开展,外部推广需验证。
  • 原文未报告盲法、样本量估算细节及经济分析具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Immediate bleeding after endoscopic sphincterotomy (EST) is a common adverse event during ERCP. However, the optimal first-line hemostatic strategy remains undefined because comparative randomized trials are lacking. We aimed to evaluate the noninferiority of a self-assembling peptide (SAP)-first strategy compared with conventional balloon tamponade for oozing-type immediate post-EST bleeding, with superiority testing performed as a prespecified exploratory analysis. METHODS: PROTECT-EST (A peptide-first hemostatic strategy for oozing-type postsphincterotomy bleeding during endoscopic retrograde cholangiopancreatography: a multicenter noninferiority randomized controlled trial) was a multicenter, investigator-initiated, parallel-group randomized controlled trial conducted at tertiary referral centers in Japan. Adults with oozing-type bleeding persisting for ≥180 seconds after EST without spontaneous hemostasis were randomly assigned (1:1) to SAP application or balloon tamponade as the initial hemostatic strategy. The primary end point was successful initial hemostasis, defined as the absence of active oozing for ≥3 minutes after the assigned intervention. Noninferiority was tested first, and superiority was assessed as a prespecified exploratory analysis. RESULTS: A total of 130 patients were randomized (SAP group, n = 65; balloon group, n = 65). SAP met the prespecified noninferiority criterion. In the prespecified exploratory superiority analysis, successful initial hemostasis occurred in 60 of 65 patients (92.3%) in the SAP group and 50 of 65 patients (76.9%) in the balloon group (risk difference, 15.4 percentage points; 95% CI, 3.1-27.7; P = .027). The mean time to completion of the initial hemostatic intervention was shorter in the SAP group, and rescue hemostatic devices were required less frequently (7.7% vs 23.1%; P = .033). Adverse events and delayed hemorrhage were similar between groups. In supportive bootstrap-based economic analyses, the SAP-first strategy was generally more effective and not more costly. CONCLUSIONS: In this noninferiority trial, a SAP-first strategy was noninferior to balloon tamponade for oozing-type immediate post-EST bleeding and, in exploratory analyses, was associated with higher initial hemostasis, shorter procedure time, and less rescue device use. SAP may represent a practical first-line option, although external validation is warranted.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Ogura T, Ikeura T, Takenaka M, et al. A peptide-first hemostatic strategy for oozing-type postsphincterotomy bleeding during endoscopic retrograde cholangiopancreatography: a multicenter noninferiority randomized controlled trial (PROTECT-EST). Gastrointest Endosc. 2026. PMID: 42250776. doi:10.1016/j.gie.2026.05.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。